Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer.
Nine patients with thyroid cancer were treated with reserpine in an attempt to reduce radiation exposure to the salivary glands from 100-150 mCi doses of I-131 therapy to thyroid remnants or metastases. Three control patients were not treated with reserpine but did receive 100-150 mCi of I-131. Parotid/background ratios of activity after radioablative doses of I-131 in patients not treated with reserpine were significantly higher than the patients treated with reserpine, and this was also true seven days after the radioablative dose. Combined therapy with reserpine, chewing gum, lemon candies, and hydration is suggested for the prevention of sialadenitis and xerostomia due to large doses of radioiodine.
D000230:Adenocarcinoma / Q000532:radiotherapy; D002291:Carcinoma, Papillary / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000378:metabolism* / Q000627:therapeutic use; D010306:Parotid Gland / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D011832:Radiation Injuries / Q000517:prevention & control; D012110:Reserpine / Q000627:therapeutic use*; D012469:Salivary Glands / Q000187:drug effects / Q000378:metabolism*; D012793:Sialadenitis / Q000209:etiology / Q000517:prevention & control; D012796:Sialography; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
D007457:Iodine Radioisotopes; D012110:Reserpine